ZnO NANOPARTICLES TAGGED PHARMACEUTICALS FOR IMPROVED DRUG DELIVERY AND METHOD OF TAGGING

ZnO nanoparticles tagged to pharmaceuticals address the bioavailability issues of current drugs by neutralizing stomach acids, allowing for lower doses and maintaining physiological pH, enhancing treatment efficacy.

WO2024246917A1PCT designated stage expired Publication Date: 2024-12-05PALICHA KAUSHIK +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2023/050694
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2023-07-17
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current orally administered drugs face challenges in bioavailability due to protonation in the stomach, leading to acidic environments and the need for higher doses, which complicates the release of active drug components.

Method used

Zinc Oxide (ZnO) nanoparticles are tagged to pharmaceuticals to facilitate improved drug delivery, allowing for reduced dosages and maintaining physiological pH by neutralizing protons, thereby enhancing bioavailability and reducing acid formation.

Benefits of technology

The ZnO tagged pharmaceuticals achieve significant bioavailability with substantially lower doses, maintaining physiological pH and effectively delivering drugs by neutralizing stomach acids, thus improving treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IN2023050694_05122024_PF_FP_ABST
    Figure IN2023050694_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides Zinc Oxide (ZnO) nanoparticles tagged pharmaceuticals for improved drug delivery, wherein a specific pharmaceutical for a specific disorder is tagged with ZnO nanoparticles to be administered to an animal. The ZnO tagged pharmaceuticals exhibit good coordination with the Pt electrode surface, breaking down of the drug within the potential window of aqueous medium (-1.2 to 1.2V) (the breaking down of the ZnO tagged drug mimics the intended elements required from a drug for a specific biological effect in a human body condition). ZnO tagged pharmaceuticals suppress formation of large amounts of acid in the stomach that helps in release of the desired products from the drug for bioavailability. The amount of ZnO tagged pharmaceutical required is of the order of 1000 times lesser in comparison to the untagged form.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]TITLE ZnO NANOPARTICLES TAGGED PHARMACEUTICALS FOR IMPROVED DRUG DELIVERY AND METHOD OF TAGGING CROSS REFERENCE TO RELATED APPLICATIONS The present application is based upon and claims priority to India complete patent application number 202341037882 filed on June 01, 2023, titled “ZnO nanoparticles tagged pharmaceuticals for improved drug delivery and method of tagging”, the entire contents of which is herein incorporated by reference. FIELD The present disclosure relates to Zinc Oxide (ZnO) nanoparticles tagged pharmaceuticals for improved drug delivery. ACKNOWLEDGEMENTS: The applicants thank WBR labs (Chennai, Tamil Nadu, India) for carrying out the drug analysis of the blood samples, and IIT Madras, Department of Chemistry for FTIR, UV-Vis and XRD analysis of the drugs in their original forms as procured from the market, and their ZnO tagged forms prepared according to the teachings of the present disclosure. DEFINITION As used in the present disclosure, the following terms are generally intended to have the meaning as set forth below, except to the extent that the context in which they are used indicates otherwise. The terms “ZnO tagging”, “ZnO tagged”, “ZnO nanoparticles tagged” “tagged with ZnO”, or “tagged to ZnO” and the like, means pharmaceuticals / drugs tagged or tagging (to indicate the process of tagging) of the pharmaceuticals with Zinc oxide nanoparticles by a physical method. It is to be noted that, while the experiments have been conducted on certain specific ZnO tagged drugs or a combination of them, however, the invention is not limited to those specific drugs, but includes other drugs that exhibit potential effectiveness and efficacy through ZnO tagging according to the teachings in the present disclosure. The terms “ECOSPRIN” or “ECOSPRIN 75mg”, or “ECOSPRIN 75mg Tablet” may have been used interchangeably, which means the pharmaceutical blood thinner product marketed with the name ECOSPRIN 75mg Tablet. The terms “ECOSPRIN I” or “ECOSPRIN-I”, wherein the second term is with a hyphen, is to mean in the context of the present disclosure the small tablet with light orange coating inside the CITIMET capsule, wherein the CITIMET capsule in all includes ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and the ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule), wherein these contents are secured within a two piece capsule covering, generally in red and green. As used herein, the term “ZnO tagged CITIMET” or “ZnO tagged CITIMET capsule” may have been used interchangeably, which means the pharmaceuticals included in the CITIMET capsule, which have been ZnO tagged, which more particularly means the ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and the ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule), wherein, in a CITIMET capsule the amount of CITICOLINE in the crystalline powder is 475mg, and amount of ECOSPRIN-I is 25mg. As used herein, the terms “COMBINATION DRUG PRODUCT” or “ZnO tagged COMBINATION DRUG PRODUCT” in the context of the experiments performed and exemplary embodiments in the present invention means the combination of three ingredients i.e., the ZnO tagged ECOSPRIN 75 mg Tablet, ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule). It is to be noted that, while the experiments have been conducted on certain specific ZnO tagged drugs or a combination of them, however, the invention is not limited to those specific drugs, but includes other drugs that exhibit potential effectiveness and efficacy through ZnO tagging according to the teachings in the present disclosure. BACKGROUND Biomedical applications of Zinc Oxide (ZnO) nanomaterials have recently been explored in the field of cancer therapy as disclosed in the following literature. Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin Drug Deliv.2010;7(9):1063–1077. Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X. A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials. 2011;32:1906– 1914. Specific properties and characteristics of ZnO, such as biocompatibility, their inherent toxicity against cancerous cells, their ability to induce intracellular ROS generation, ease of functionalization, easy synthesis make them an appealing candidate for biomedical applications. CN106362162B discloses an antitumour drug carrier ZnO@PMAA-b-PHPMA quantum dots formed from N- (2- hydroxypropyl) Methacrylamide (HPMA) and methacrylic acid (MAA). The Chinese patent also discloses that when the pH is less than 5.0, the ZnO quantum dots can be acidified, destroyed and hydrolyzed, so that the loaded drugs reach the lesion site, triggering the release of antitumor drugs from the carrier, which not only reduces the drug toxicity, it can also intelligently release anticancer drugs in tumor cells, improve the bioavailability of drugs. Several researchers have also reported chemotherapeutics based on ZnO. Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X. A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials. 2011;32:1906– 1914. Al-Ajmi MF, Hussain A, Ahmed F. Novel synthesis of ZnO nanoparticles and their enhanced anticancer activity: role of ZnO as a drug carrier. Ceram Int. 2016;42:4462–4469. Kishwar S, Asif MH, Nur O, Willander M, Larsson PO. Intracellular ZnO nanorods conjugated with protoporphyrin for local mediated photochemistry and efficient treatment of single cancer cell. Nanoscale Res Lett.2010;5:1669. Xie H. Catalase immobilized ZnO nanorod with b-cyclodextrin functionalization for electrochemical determination of forchlorfenuron. Int J Electrochem Sci. 2016;11:2612–2620. Drug loading, release mechanism and cytotoxicity of various ZnO-drug composites have also been studied in the following literature. Cai X, Luo Y, Zhang W, Du D, Lin Y. pH-Sensitive ZnO quantum dots−doxorubicin nanoparticles for lung cancer targeted drug delivery. ACS Appl Mater Interfaces.2016;6b:04933. Guo D, Wu C, Jiang H, Li Q, Wang X, Chen B. Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. J Photochem Photobiol B.2008;93:119–126. Muhammad F, Guo M, Guo Y, et al. Acid degradable ZnO quantum dots as a platform for targeted delivery of an anticancer drug. J Mater Chem. 2011;21:13406. Tripathy N, Ahmad R, Ko HA, Khang G, Hahn YB. Enhanced anticancer potency using an acid-responsive ZnO-incorporated liposomal drug-delivery system. Nanoscale.2015;7:4088–4096. Capping ZnO with ligands such as amino acids (both enantiomers and racemic mixture) is found to increase the electronic conductivity via band gap reduction in capped ZnO and hence be used as semiconductor material in heterojunction diode and photovoltaic applications as extensively studied in the following literature: E. Indubala, M.Dhanasekar, V. Sudha, E. J. Padma Malar, P. Divya, JosittaSherine, RevathyRajagopal, S.Venkataprasad Bhat, S. Harinipriya, “L – Alanine capping of ZnO nanorods: Increased carrier concentration in ZnO / CuI heterojunction diode” RSC Adv., 8, 2018, 5350 – 5361. The drugs produced currently by pharmaceutical companies, especially when taken orally are protonated by HCl in the stomach. Based on the drug formula, by such protonation, more and more acids are released as the drugs are digested (for example, release of phosphoric acid in case where the drug includes citicoline having Mol. Formula: C14H26N4O11P2 or C14H27N4O11P2+salt), which makes the pH of the physiological medium much more acidic (locally), thus making it difficult to release the desired product for bioavailability, which necessitates intake of higher doses of the drug with the aim of achieving bioavailability of the drug in the desired amount. Therefore, orally administered drugs currently available are always taken in higher doses of mg, and if the amount of drug taken is high, more protons are released, adding to the acidic environment problem as stated above. As a solution, the present disclosure aims at providing Zinc Oxide (ZnO) nanoparticle tagged pharmaceuticals for improved drug delivery, where substantially lesser amount of ZnO tagged pharmaceuticals are required, which would eliminate the formation of large amounts of acids, and greatly increase the bioavailability of the drugs. SUMMARY The present disclosure provides Zinc Oxide (ZnO) nanoparticles tagged pharmaceuticals for improved drug delivery, wherein a specific pharmaceutical for a specific disorder is tagged with ZnO nanoparticles to be administered to an animal. The ZnO tagged pharmaceuticals exhibit good coordination with the Pt electrode surface, breaking down of the drug within the potential window of aqueous medium (-1.2 to 1.2V) (the breaking down of the ZnO tagged drug mimics the intended elements required from a drug for a specific biological effect in a human body condition). In an embodiment of the present disclosure, ZnO is tagged to neurotransmitters and blood thinner pharmaceutical samples. BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS Fig.1 illustrates XRD analysis of the ZnO tagged pharmaceutical compositions of ECOSPRIN 75 mg Tablet, ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and CITICOLINE (the white crystalline powder inside the CITIMET capsule). Fig.2 illustrates FTIR spectrum of ZnO tagged ECOSPRIN 75mg Tablet. Fig. 3 illustrates FTIR spectrum of ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule). Fig. 4 illustrates FTIR spectrum of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule). Fig. 5 illustrates UV-Vis spectra of the ZnO tagged pharmaceutical compositions of ECOSPRIN 75 mg Tablet, ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and CITICOLINE (the white crystalline powder inside the CITIMET capsule). Fig. 6 illustrates Cyclic Voltammogram of ZnO tagged ECOSPRIN 75mg Tablet coated on Pt working electrode in a three-electrode system. Fig. 7 illustrates Cyclic Voltammogram of ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) coated on Pt working electrode in a three-electrode system. Fig. 8 illustrates cyclic voltammogram of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule) coated on Pt working electrode in a three-electrode system. Fig. 9 illustrates cyclic voltammogram of the ZnO tagged COMBINATION DRUG PRODUCT i.e., combination of ZnO tagged ECOSPRIN 75 mg Tablet, and the ZnO tagged CITIMET Capsule coated on Pt working electrode in a three- electrode system. Fig. 10 illustrates the mechanism of break-down of ZnO tagged ASPIRIN (acetyl salicylic acid) present in the ZnO tagged ECOSPIRIN 75mg Tablet tagged with ZnO through hydrolysis into salicylic acid and acetic acid. Fig. 11 illustrates the mechanism of oxidation of ZnO tagged ATORVASTATIN present in the ZnO tagged ECOSPRIN 75mg Tablet. Fig. 12 illustrates the mechanism of oxidation of ZnO tagged CLOPIDOGREL present in the ZnO tagged ECOSPRIN 75mg Tablet. Fig. 13 illustrates the mechanism of oxidation of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule, which is tagged with ZnO). DETAILED DESCRIPTION The preferred embodiments of the present disclosure will be described in detail with the following disclosure and examples. The foregoing general description and the following detailed description are provided to illustrate only some embodiments of the present disclosure and not to limit the scope of the present disclosure. The disclosure is capable of other embodiments and can be carried out or practiced in various other ways. Unless otherwise specified, all the technical and scientific terms used herein have the same meaning as is generally understood by a person skilled in the art pertaining to the present disclosure. Headings are used solely for organizational purposes, and are not intended to limit the disclosure in any way. The use of the singular includes the plural unless specifically stated otherwise. As used herein, the singular forms “a,” “an” and “the” are intended to include the plural forms as well. The use of “or” means “and / or” unless stated otherwise. As used herein, the terms “comprises” and / or “comprising” specify the presence of the stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. Furthermore, to the extent that the terms “includes,” “having,” “has,” “with,” “composed,” “comprised” or variants thereof are used in either the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising.” As used herein, ranges and amounts can be expressed as “about” a particular value or range. “About” is intended to also include the exact amount. Hence “about 5 percent” means “about 5 percent” and also “5 percent.” “About” means within typical experimental error for the application or purpose intended. It is to be understood that wherein a numerical range is recited, it includes all values within that range, and all narrower ranges within that range, whether specifically recited or not. Reference throughout this specification to “one embodiment,” “an embodiment,” “one example,” or “an example” means that a particular feature, structure, or characteristic described in connection with the embodiment or example is included in at least one embodiment of the present disclosure. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” “one example,” or “an example” in various places throughout this specification are not necessarily all referring to the same embodiment or example. Furthermore, the particular features, structures, or characteristics may be combined in any suitable combinations and / or sub-combinations in one or more embodiments or examples. In addition, it should be appreciated that if any figures are provided herewith, they are for explanation purposes to persons ordinarily skilled in the art and that the drawings of them are not necessarily drawn to scale. In this specification, certain aspects of one embodiment include process steps and / or operations and / or instructions described herein for illustrative purposes in a particular order and / or grouping. However, the particular order and / or grouping shown and discussed herein are illustrative only and not limiting. Those of skill in the art will recognise that other orders and / or grouping of the process steps and / or operations and / or instructions are possible and, in some embodiments, one or more of the process steps and / or operations and / or instructions discussed above can be combined and / or deleted. In addition, portions of one or more of the process steps and / or operations and / or instructions can be re-grouped as portions of one or more other of the process steps and / or operations and / or instructions discussed herein. Consequently, the particular order and / or grouping of the process steps and / or operations and / or instructions discussed herein do not limit the scope of the disclosure. The present disclosure provides Zinc Oxide (ZnO) nanoparticles tagged pharmaceuticals for improved drug delivery, wherein a specific pharmaceutical for a specific disorder is tagged with ZnO nanoparticles to be administered to an animal. In an embodiment, for the experiments of the present disclosure, ZnO is tagged to neurotransmitters and blood thinner pharmaceutical samples. The pharmaceutical samples investigated were as below, wherein the pharmaceuticals were tagged with ZnO. 1. ZnO tagged ECOSPIRIN 75mg Tablet is composed of: − Aspirin 75 mg, − Atorvastatin 10mg, and − Clopidogrel, − TiO2as pigment, and orange dye, − ZnO (through tagging). 2. ZnO tagged CITIMET capsule is composed of: − Citicoline as a white crystalline powder inside the capsule, − ECOSPRIN-I i.e., a small orange tablet inside the capsule comprising Aspirin and Clopidogrel (with TiO2as pigment, and orange dye), − ZnO (through tagging). Method of tagging ZnO nanoparticles on the pharmaceuticals ZnO tagging to the pharmaceuticals can be performed by any suitable methods known to a person skilled in the art, in an aspect of the present disclosure, ZnO tagging to the pharmaceuticals has been performed in the following manner. − obtaining a pharmaceutical powder; − adding Zinc Oxide (ZnO) nanoparticles powder to the pharmaceutical powder; and − grinding together the pharmaceutical powder and the ZnO powder in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form a fine powder mixture of ZnO tagged pharmaceutical. The fine powder mixture of ZnO tagged pharmaceutical is of a particle size of 500 nm to 700 nm. Method of preparing ZnO tagged ECOSPRIN 75mg Tablet − ECOSPRIN 75mg Tablet was ground in a mortar pestle to form a fine powder, − Zinc Oxide (ZnO) powder was added to the ECOSPRIN 75mg Tablet powder, and ground together to form a fine mixture powder in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form the ZnO tagged ECOSPRIN 75mg. Method of preparing ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) − ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) was ground in a mortar pestle to form a fine powder, − Zinc Oxide (ZnO) powder was added to the ECOSPRIN-I powder, and ground together in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form a fine mixture powder to form the ZnO tagged ECOSPRIN-I. Method of preparing ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule) − CITICOLINE (the white crystalline powder inside the CITIMET capsule) was mixed with Zinc Oxide (ZnO) powder, and ground together in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form a fine mixture powder of ZnO tagged CITICOLINE. Method of preparing ZnO tagged COMBINATION DRUG PRODUCT − ECOSPRIN 75mg Tablet was ground in a mortar pestle to form a fine powder, − CITICOLINE powder (the white crystalline powder inside the CITIMET capsule) was mixed with the ground fine powder of ECOSPRIN 75mg Tablet to form a mixture of the two ingredients. − ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) was added to the powder mixture of ECOSPRIN 75mg Tablet and CITICOLINE, and together ground in the mortar pestle to form a mixture of the three ingredients, − Zinc Oxide (ZnO) powder was added to the mixture of the three ingredients, and ground together in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form a fine mixture powder of ZnO tagged COMBINATION DRUG PRODUCT. It is to be noted, as would be evident to a person skilled in the art, the pharmaceutical before ZnO tagging may be a pharmaceutical or a combination of pharmaceuticals available in the market under prescription by a physician (includes a doctor, a medicine specialist, or a surgeon) or the pharmaceutical before ZnO tagging may be an over-the-counter (OTC) medicine, or a combination of different OTC medicines. XRD analysis of the ZnO tagged pharmaceuticals: Fig. 1 illustrates XRD analysis of the ZnO tagged pharmaceutical compositions of ECOSPRIN 75 mg Tablet, ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and CITICOLINE (the white crystalline powder inside the CITIMET capsule). Observations from the XRD peaks are summarised in Tables 1, 2, and 3. Table 1 S. No. ECOSPIRIN Remarks 75mg Tablet (ZnO tagged) peaks (2θ) 1. 12.7764 Corresponds to 11.9 peak of Atorvastatin Corresponds to 12.28 peak of Clopidogrel 2. 16.6790 Corresponds to 15.59 peak of Aspirin 3. 19.7144 Corresponds to 18.13 peak of Aspirin 4. 19.8589 Sharp and highly crystalline peaks Corresponds to 19.1200 peak of Atorvastatin Corresponds to 19.1200 peak of Atorvastatin 5. 20.2058 Corresponds to 20.6400 peak of Aspirin 6. 21.3911 Corresponds to 21.6900 peak of Clopidogrel 7. 21.5356 Corresponds to 21.6900 peak of Clopidogrel Corresponds to 22.6100 peak of Aspirin 8. 23.2123 Corresponds to 23.0000 peak of Clopidogrel Corresponds to 23.2000 peak of Aspirin 9. 29.6300 Corresponds to (101) peak of TiO2 / ZnO 10. 36.1633 Corresponds to 36.07 peak of Aspirin 11. 37.8110 Corresponds to (004) peak of TiO2 / ZnO12. 39.5155Corresponds to (112) peak of TiO2 / ZnO 13. 43.3325 Corresponds to 43.51 peak of Aspirin 14. 48.593915. 48.7673Corresponds to (200) peak of TiO2 / ZnO Table 2 S. No. ECOSPRIN-I Remarks (Small tablet inside CITIMET capsule) (ZnO tagged) PEAKS (2θ) 1. 7.9487 Corresponds to 8.78 peak of Clopidogrel 2. 8.0932 3. 9.7988 Corresponds to 9.62 peak of Clopidogrel 4. 15.8117 Corresponds to 15.59 peak of Aspirin 5. 15.8696 6. 20.9574 Corresponds to 20.64 peak of Aspirin 7. 22.7208 Corresponds to 22.61 peak of Aspirin 8. 22.8943 Corresponds to 23.00 peak of Clopidogrel 9. 23.4725 Corresponds to 23.20 peak of Aspirin Corresponds to 23.26 peak of Clopidogrel 10. 27.1727 Corresponds to 27.08 peak of Clopidogrel 11. 28.9651 Corresponds to 110 peaks of TiO2 / ZnO 12. 32.9833 Corresponds to 32.73 peak of Clopidogrel Table 3 S. No. CITICOLINE Remarks (the white crystalline powder inside the CITIMET capsule) (ZnO tagged) PEAKS (2θ) 1. 16.3899 2. 18.1244 Unidentified peaks, may be colourant 3. 19.8589 4. 19.9167 Corresponds to 20.5080, 21.3300, 22.2200, 22.3660 5. 21.8825 highly sharp crystalline peaks for Citicoline 6. 23.2990 7. 24.8601 Corresponds to 101 peaks of TiO2 / ZnO 8. 25.9297 9. 27.3173 10. 29.2541 Corresponds to 110 peaks of TiO2 / ZnO 11. 29.3698 12. 31.6246 13. 34.5733 Corresponds to 101 peaks of TiO2 / ZnO 14. 37.5509 Corresponds to 004 peak of TiO2 / ZnO 15. 46.5703 Corresponds to 200 peaks of TiO2 / ZnO 16. 55.9366 Corresponds to 211 peaks of TiO2 / ZnO Please Note: The peaks of TiO2, and that of ZnO were not visibly distinguished which indicates the peaks of TiO2 and of the ZnO are overlapped. FTIR analysis of the ZnO tagged pharmaceuticals Fig.2 illustrates FTIR spectrum of ZnO tagged ECOSPRIN 75mg Tablet. Fig. 3 illustrates FTIR spectrum of ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule). Fig. 4 illustrates FTIR spectrum of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule). Fig. 2 to 4 confirms the presence of functional groups such as carboxyl, alcohol, ether, esters, aldehydes, ketones, aromatic groups, hetero atomic groups in the pharmaceutical formulation of the tested pharmaceutical formulations of ECOSPRIN 75 mg Tablet, ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and CITICOLINE (the white crystalline powder inside the CITIMET capsule).as shown in Table 4. Table 4 Peaks obtained Drug name or (WAVENUMBER Remarks description IN cm-1) ECOSPIRIN 3423.03(very Wave Assigned Wave Assigned 75mg Tablet broad), 2914.88, No Functional No (cm- Functional (ZnO tagged) 2852.2, 2674.78, (cm-1) Group1) Group 2555.22, 1657.52, 3397.4 –NH 2970.1 C-H 1610.27, 1533.13, stretching 1484.92, 1379.82, 1395.2 C-N 1684.2 C=O 1235.18, 1135.87, saturated 1075.12, 1015.34, acyclic 936.271, 834.062, 1644.9 C=N 1710 C=O 782.958, 715.461, saturated acyclic 597.825, 558.2912, 557.327, 458.975 3316.4 Aliphatic 3338 Aliphatic primary primary amine amine ECOSPRIN-I Broad peaks with Wave number Assignment (Small tablet multiplets at cm-1 inside 3021.91, 2894.63, 3450 OH Carboxylic CITIMET 2698.89, 2544.61, 2954, 3077, 3119 Chlorophenyl CH Stretch capsule) 1753.94, 1691.27, 2464 C-S-C stretch 1605.45, 1457.92, (ZnO tagged) 1752 C=O carboxylic 1370.18, 1307.50, 1474,1496 Chlorophenyl ring stretch 1167.94, 1093.44, 1012.45, 916.986, 1439, 1383 Pyridine methylene wag 833.098, 754.995, 1188 C-O carboxylic acids 666.285, 598.789, 1298, 1275 Methylene twist 514.901, 422.334 1221 Chlorophenyl C-Cl stretch and bends 1154 Pyridine ring stretch 1068, 1028, Pyridine-methylene rock 1014, 993 749, 724, 697 Chlorophenyl spatial bendCITICOLINE3369.03, 2899.45,Presence of three functional groups. A benzene 1652.70, 1462.74, ring (aromatic group), a carboxylic acid (COOH) (the white 1164.79, 1115.62, group and an ester (R-C(=O)-O-R) group. Very crystalline 1055.84, 1029.80, broad peak at 3100 to 3300 cm-1proves the powder inside 989.304, 872.631, presence of COOH group. The compound has the CITIMET 710.64, 614.217, C=O (acid), C=O (ester), C–O (acid), C–O capsule) 434.869 (ester), O–H, –CH3, benzene ring and H3PO4 functional groups. (ZnO tagged) UV-Visible analysis of the ZnO tagged pharmaceuticals: Fig. 5 illustrates UV-Vis spectra of the ZnO tagged pharmaceutical compositions of ECOSPRIN 75 mg Tablet, ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule), and CITICOLINE (the white crystalline powder inside the CITIMET capsule). ZnO tagged ECOSPIRIN 75mg Tablet shows peak at 268 nm, broad peak from 240-300 nm. This is attributed to the presence of (i) Aspirin (peak at 265 nm), (ii) Clopidogrel (peak at 254nm), (iii) Atorvastatin (maxima at 237 nm and minima at 261 nm). All peaks combine and show a broad spectrum around 240 to 300 nm. As observed from Fig. 5, ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule) shows peak at 283 nm due to the presence of diphosphocholine of CITICOLINE. ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) shows peaks at 288 nm, and 396 nm, where, the peak at 288 nm is attributed to citicoline and the peak at 396 nm is the presence of TiO2as pigment and also of the tagged ZnO, wherein the peaks of TiO2and of the ZnO are overlapped. Examples: The present disclosure will now be explained in further detail by the following examples. These examples are illustrative of certain embodiments of the disclosure without limiting the scope of the present disclosure. A three-electrode electrochemical assembly for break down of the pharmaceuticals were prepared by employing a borosil glass container covered with a three-inlet enabled Teflon cover, wherein, − In the first inlet: a working Platinum (Pt) electrode (cathode) coated with a ZnO tagged pharmaceutical, − In the second inlet: ‘Saturated Calomel’ as reference electrode (anode), − In the third inlet: a Pt wire counter electrode, and − 1M KCl as electrolyte. Electrochemical action of three electrode assembly: Cyclic voltammetry (CV) was conducted at different scan rates from 1 to 200 mVs-1in the potential window of -1.2 to 1.2 V to observe the redox behavior of the electrochemical break down (electro-catalyzation) of the ZnO tagged pharmaceuticals. Example 1 Cyclic Voltammogram of ZnO tagged ECOSPRIN 75mg Tablet Fig. 6 illustrates Cyclic Voltammogram of ZnO tagged ECOSPRIN 75mg Tablet coated on Pt working electrode in the three-electrode system. Comparison of the scan rate, peak potential, and peak current for ZnO tagged ECOSPRIN 75mg Tablet at different scan rates is provided in Table 5. Table 5 S. Scan rate Voltage (V) Current (mA) No (mVs-1) 1. 1 Forward Scan: Peak @ - 0.2; Hump @ 0.6 -0.6; -0.5 Reverse Scan: Hump @ - 0.6 -0.4 2. 5 Forward Scan: Peak @ - 0.01; Hump @ 0.15; Hump @ - 0.3; - 0.5; - 0.4 0.75 Reverse Scan: - 0.6 Hump @ - 0.5 Forward Scan: Peak @ 0.1; Hump @ -0.9; Hump @ - 0.2; - 0.7; - 0.2; 0.25; Hump @ 0.9 - 0.4 Reverse Scan: Hump @ 0.9; Hump @ - 0.6; Hump @ - - 0.5; - 0.7; - 0.8 0.9 Forward Scan: Peak @ 0.2; Hump @ 0.99; Hump @ - 0.2; - 0.1; - 0.3; 0.4; Hump @ 0.5 - 0.15 Hump @ 1.05 - 0.2 Reverse Scan: Hump @ - 0.5; Peak @ -0.9; Hump @- - 0.6; - 0.8; - 0.9 1.05 Forward Scan: Peak @ 0.4; Hump @ -1.05; Hump @ - 0.3; - 0.3; - 0.7; 0.6; Hump @ 0.49 0.1 Hump @ 0.65 - 0.2 Reverse Scan: Hump @ - 0.6; Hump @-1.05 - 1.0; - 1.1 Forward Scan: Peak @ 0.49; Hump @ 0.8; Hump @ 0.4; 0.05; - 0.3; 1.0; Hump @ 0.5 0.2 Hump @ 1.05 - 0.3 Reverse Scan: Hump @ - 0.7; Hump @-1.05 - 0.4; - 1.1 Forward Scan: Peak @ 0.65; Hump @ 0.8; Hump @ 0.45; 0.25; - 0.10 1.05 Reverse Scan: - 1.15; - 0.9 Hump @ - 0.71; Hump @ -1.01 Forward Scan: Small Peak @ -0.75; Hump @ -1.00; 0.5; 0.2; 0.2; -1.3; Peak @ 0.6; Hump @ 0.8; Hump @ 1.05 -1.35 Reverse Scan: Small Peak @ - 0.79; Hump @-1.05 - 0.8; -1.25 Forward Scan: Peak @ 0.6; Hump @ 0.9; Hump @ - 0.43; 0.22; - 0.3 0.75; Reverse Scan: -1.3; -1.1 Hump @ 0.99; Hump @-0.5 10. 175 Forward Scan: Peak @ 0.65; Hump @ -1.01; Hump @ 0.6; -0.8; 0.5 0.92 Reverse Scan: -0.1; -1.3; -1.4 Hump @ 0.89; Peak @ -0.9; Hump @- 1.15 11. 200 Forward Scan: Peak @ 0.75; Hump @ -1.05; Hump @ - 0.7; -0.85; -0.75; 0.75; Hump @ 0.98 0.4 Reverse Scan: Hump @ 0.8; Hump @ -0.75; Hump @- 1.15 -0.2; -1.35; -1.45 As observed through Table 5, and Fig. 6, the values of redox potential and current at 100 mVs-1scan rate agrees satisfactorily with as described in the literature: Senee Kruanetr, Pat Pollard and Carlos Fernandez, Radhakrishna Prabhu, Electrochemical Oxidation of Acetyl Salicylic Acid and its voltametric sensing in real samples at a sensitive edge plane Pyrolytic Graphite Electrode modified with Graphene, International Journal of Electrochemical Science, 9 (2014), 5699- 5711. In the literature, the oxidation potential of aspirin occurs at 0.7 V on edge plane pyrolytic graphite modified with graphene with respect to Ag / AgCl reference electrode. In the present disclosure, the oxidation peak is observed at 0.65 V vs SCE for ZnO tagged ECOSPIRIN 75mg tablet drop casted on Pt working electrode. The shift of 50 mV from the literature value may be attributed to the change in the reference electrode from Ag / AgCl (literature) to SCE (present studies). The rationale could also be due to the interaction between the drug carrier (Bulk ZnO) and the drug (ECOSPIRIN 75mg Tablet). Two small humps were noticed at 0.8 and 1.05 V in the forward scan. The peak at 0.8 V could be due to oxidation of atorvastatin. The literature iterates that atorvastatin oxidizes on glassy carbon electrode at 1.004 V (vs Ag / AgCl) at 100 mV / s as shown in the following literature. − B. Yilmaz* and S. Kaban, Electrochemical Behavior of Atorvastatin at Glassy Carbon Electrode and its Direct Determination in Pharmaceutical Preparations by Square Wave and Differential Pulse Voltammetry, Indian Journal of pharmaceutical science, 2016, 78 (3) : 360 – 367. − Ramona Oana Gunache (Ro^ca), Alexandra Virginia Bounegru, Constantin Apetrei, Determination of Atorvastatin with Voltametric Sensors Based on Nanomaterials, Inventions, 2021, 6, 57-72. The shift in the oxidation potential of atorvastatin to the lower side of 204 mV in the present studies could be attributed to the change in (i) working electrode from GCE to Pt coated with ZnO tagged ECOSPRIN via drop casting method, (ii) the reference electrode from Ag / AgCl to SCE and (iii) weak interaction between ZnO tagged ECOSPRIN. The oxidation peak observed at 1.05V accounts for the Clopidogrel base present in the pharmaceutical formulation. The observed oxidation potential of Clopidogrel is identical to that of the following literature − Dermiş, S.; Aydoğan, E., Electrochemical study of the antiplatelet agent clopidogrel and its determination using differential pulse voltammetry in bulk form and pharmaceutical preparations with a glassy carbon electrode, Pharmazie, 2010, 65, 3. Based on the above observations in the Cyclic Voltammogram of ZnO tagged ECOSPIRIN 75mg Tablet drop casted on Pt electrode, the plausible mechanism for the break-down of the drug can be attained as follows Fig. 10 illustrates the mechanism of break-down of ZnO tagged ASPIRIN (acetyl salicylic acid) present in the ZnO tagged ECOSPIRIN 75mg Tablet tagged with ZnO through hydrolysis into salicylic acid and acetic acid. The peak in the forward scan at 0.65 V is due to the formation of salicylic acid by hydrolysis of acetyl salicylic acid tagged with ZnO and drop casted on Pt electrode. Fig. 11 illustrates the mechanism of oxidation of ZnO tagged ATORVASTATIN present in the ZnO tagged ECOSPRIN 75mg Tablet. The two small humps noticed at 0.8 and 1.05 V in the forward scan of the cyclic voltammogram of ECOSPRIN 75mg Tablet denotes the oxidation via removal of two electrons from ATORVASTATIN with subsequent hydrolysis leading to the formation of 5-(4-Fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic) acid at 0.8 V and 3,5-dihydroxy-7-oxo-heptanoic acid at 1.05 V. Fig. 12 illustrates the mechanism of oxidation of ZnO tagged CLOPIDOGREL present in the ZnO tagged ECOSPRIN 75mg Tablet. The oxidation peak observed at 1.05V also accounts for the hydrolysis of clopidogrel base into acetaldehyde and Methyl (+)-(S)-α-(o-chlorophenyl)-6,7- dihydrothieno[3,2-c] pyridine-5(4H)-ol. Example 2 Cyclic Voltammogram of ZnO tagged ECOSPRIN-I Fig. 7 illustrates Cyclic Voltammogram of ZnO tagged ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) coated on Pt working electrode in the three-electrode system. Table 6 shows the comparison of the scan rate, peak potential, and peak current for ECOSPRIN-I at different scan rates (25, 50, 75 and 100 mV / s). Table 6 S. No Scan rate (mVs-1) Voltage (V) Current (mA) 1. 25 Forward Scan: Peak @ 0.55; 1 Reverse Scan: Hump @ - 0.55; Peak @ -0.7 - 0.5; - 0.7; 2. 50 Forward Scan: Peak @ 0.62; Hump @ 1.05; 0.3; - 0.9; Reverse Scan: Hump @ - 0.6; Hump @- -0.9; - 1.0; - 1.05 1.1 3. 75 Forward Scan: Peak @ 0.5; 1; Reverse Scan: Hump @ - 0.49; peak @-0.6 - 0.6; - 0.6 4. 100 Forward Scan: Peak @ 0.65; Hump @ 0.9; 1.2; 0.40; Reverse Scan: Hump @ - 0.71; Hump @ - - 0.5; - 0.7 1.01 From Table 6, and Fig. 7, the values of redox potential and current at 100 mVs-1scan rate (cf. Fig …) agrees satisfactorily with the following literature. Senee Kruanetr, Pat Pollard and Carlos Fernandez, Radhakrishna Prabhu, Electrochemical Oxidation of Acetyl Salicylic Acid and its voltammetric sensing in real samples at a sensitive edge plane Pyrolytic Graphite Electrode modified with Graphene, International Journal of Electrochemical Science, 9 (2014), 5699- 5711. In the literature, the oxidation potential of aspirin occurs at 0.7 V on edge plane pyrolytic graphite modified with graphene with respect to Ag / AgCl reference electrode. In the present investigation oxidation peak is observed at 0.55 to 0.65 V vs SCE for ZnO tagged with Ecospirin drop casted on Pt working electrode. The shift of potential 50 to 150 meV from the literature value may be attributed to the change in the reference electrode from Ag / AgCl (literature) to SCE (present disclosure). The rationale could also be due to the interaction between the drug carrier (Bulk ZnO) and the drug (ECOSPRIN I). One small hump noticed at 1 to 1.01 V in the forward scan accounts for the clopidogrel base present in the pharmaceutical formulation. The observed oxidation potential of clopidogrel is identical to that available in the following literature. Dermiş, S. ; Aydoğan, E., Electrochemical study of the antiplatelet agent clopidogrel and its determination using differential pulse voltammetry in bulk form and pharmaceutical preparations with a glassy carbon electrode, Pharmazie, 2010, 65, 3 Example 3 Cyclic Voltammogram of ZnO tagged CITICOLINE Fig. 8 illustrates cyclic voltammogram of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule) coated on Pt working electrode in the three-electrode system. Fig. 13 illustrates the mechanism of oxidation of ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule, which is tagged with ZnO). A comparison of the scan rate, peak potential, and peak current for ZnO tagged CITICOLINE (the white crystalline powder inside the CITIMET capsule, which is tagged with ZnO) at different scan rates is provided in Table 7. Table 7 S. No Scan rate (mVs-1) Voltage (V) Current (mA) 1. 1 Forward Scan: Peak @ - 0.1 0.1 Reverse Scan: Peak @ - 0.3 -0.1 2. 5 Forward Scan: Peak @ - 0.03 0.3 Reverse Scan: Peak @ - 0.35 -0.1 3. 10 Forward Scan: Peak @ 0.1 0.01 Reverse Scan: Peak @ 0.39 - 0.15 4. 25 Forward Scan: Peak @ 0.2 0.5 Reverse Scan: Peak @ -0.35 - 0.2 5. 50 Forward Scan: Peak @ 0.27 0.7 Reverse Scan: Peak @ - 0.41 - 0.2 6. 75 Forward Scan: Peak @ 0.40 0.75 Reverse Scan: Peak @ - 0.49 - 0.4 7. 100 Forward Scan: Peak @ 0.42 0.88 Reverse Scan: Peak @ - 0.51 -0.42 8. 125 Forward Scan: Peak @ 0.49 0.95 Reverse Scan: Peak @ - 0.55 - 0.5 9. 150 Forward Scan: Peak @ 0.5 1.00 Reverse Scan: Peak @ 0.57 -0.58 10. 175 Forward Scan: Peak @ 0.52 1.10 Reverse Scan: Peak @ -0.61 -0.6 11. 200 Forward Scan: Peak @ 0.55 1.15 Reverse Scan: Peak @ -0.62 -0.65 As observed through Table 7, and Fig. 8, the values of redox potential and current at 100 mVs-1 scan rate agrees satisfactorily with the following literature. Arash Shadlaghani, Mahsa Farzaneh, Dacen Kinser and Russell C. Reid, Direct Electrochemical Detection of Glutamate, Acetylcholine, Choline, and Adenosine Using Non-Enzymatic Electrodes, Sensors 2019, 19, 447. In the literature, the oxidation potential of CITICOLINE occurs at 0.62 V on Ni- Al LDHs / CD modified Glassy Carbon Electrode (GCE) with respect to Ag / AgCl reference electrode in 1M KOH electrolyte. In the present disclosure, oxidation peak is observed at 0.43 V vs SCE for ZnO tagged with CITICOLINE drop casted on Pt working electrode. The shift of 190 mV from the literature value may be attributed to the change in the reference electrode from Ag / AgCl (literature) to SCE (present studies). The rationale could also be due to the interaction between the drug carrier (Bulk ZnO) and the drug (CITICOLINE). The oxidation peak observed at 0.43 V also accounts for the hydrolysis of CITICOLINE base into cytidine, phosphoric acid and choline. The presence of choline is manifested at 0.43 V in the cyclic voltammogram of CITICOLINE tagged to ZnO on Pt electrode vs SCE. Phosphoric acid involves in Hydrogen evolution reaction on the electrode surface, due to the dissolved H2 gas in the solution, the peak shift and peak current increase with increase in scan rate is noticed. As the hydrolysis product of CITICOLINE is cytidine an amino acid, phosphoric acid and choline – a neurotransmitter, the intake of CITICOLINE would increase the neural activities such as improvement in memory, cognitive effects, response times, improved brain functions in patients with mild and severe Autism. Tagging CITICOLINE with ZnO will provide localised drug delivery as well as good Zn supplement to the system to improve the immunity of the body. Example 4 Cyclic Voltammogram of ZnO tagged COMBINATION DRUG PRODUCT Fig. 9 illustrates cyclic voltammogram of the ZnO tagged COMBINATION DRUG PRODUCT i.e., combination of ZnO tagged ECOSPRIN 75 mg Tablet, and the ZnO tagged CITIMET Capsule coated on Pt working electrode in the three-electrode system. As discussed before, the method of preparing ZnO tagged COMBINATION DRUG PRODUCT is as given below. − ECOSPRIN 75mg Tablet was ground in a mortar pestle to form a fine powder, − CITICOLINE powder (the white crystalline powder inside the CITIMET capsule) was mixed with the ground fine powder of ECOSPRIN 75mg Tablet to form a mixture of the two ingredients. − ECOSPRIN-I (the small tablet with light orange coating inside the CITIMET capsule) was added to the powder mixture of ECOSPRIN 75mg Tablet and CITICOLINE, and together ground in the mortar pestle to form a mixture of the three ingredients, − Zinc Oxide (ZnO) powder was added to the mixture of the three ingredients, and ground together in the presence of acetone or isopropanol solvent, and left for a few minutes at room temperature to form a fine mixture powder to form the ZnO tagged COMBINATION DRUG PRODUCT. Comparison of the scan rate, peak potential, and peak current for the ZnO tagged COMBINATION DRUG PRODUCT at different scan rates is provided in Table 8. Table 8 S. No Scan rate (mVs-1) Voltage (V) Current (mA) 1. 1 Forward Scan: Peak @ - 0.2 0.15 Reverse Scan: Peak @ - 0.25; Hump -0.095; -0.025 @ -0.1 2. 5 Forward Scan: Peak @ - 0.1 0.2 Reverse Scan: Peak @ - 0.31; Hump -0.21; -0.1 @ -0.25 3. 10 Forward Scan: Peak @ -0.1 0.3 Reverse Scan: Peak @ -0.39; Hump - 0.35; -0.1 @ -0.22 25 Forward Scan: Peak @ 0.35 0.45 Reverse Scan: Peak @ -0.41; Hump - 0.19; -0.09 @ -0.37 50 Forward Scan: Peak @ 0.25 0.65 Reverse Scan: Peak @ - 0.49; Hump - 0.25; -0.12 @ -0.3 75 Forward Scan: Peak @ 0.32 0.7 Reverse Scan: Peak @ - 0.52; Hump - 0.35; -0.19 @ -0.35 100 Forward Scan: Peak @ 0.38 0.8 Reverse Scan: Peak @ - 0.59; Hump -0.42; -0.22 @ -0.41 125 Forward Scan: Peak @ 0.49 0.95 Reverse Scan: Peak @ - 0.57; Hump - 0.6; -0.54 @ -0.54 150 Forward Scan: Peak @ 0.5 1.00 Reverse Scan: Peak @ -0.68; Hump -0.58; -0.49 @ -0.57 175 Forward Scan: Peak @ 0.52 1.10 Reverse Scan: Peak @ -0.68; Hump -0.6; 0.45 @ -0.52 200 Forward Scan: Peak @ 0.58 1.5 Reverse Scan: Peak @ -0.70; Hump -0.65; -0.51 @ -0.55 Table 8 summarises the values of redox potential and current at 100 mVs-1scan rate agrees satisfactorily with the following literature for CITICOLINE formulation. Arash Shadlaghani, Mahsa Farzaneh, Dacen Kinser and Russell C. Reid, Direct Electrochemical Detection of Glutamate, Acetylcholine, Choline, and Adenosine Using Non-Enzymatic Electrodes, Sensors 2019, 19, 447. In the present disclosure, the oxidation peak is observed at 0.38 V vs SCE for ZnO tagged COMBINATION DRUG PRODUCT drop casted on Pt working electrode. The shift of 240 mV from the literature value may be attributed to the change in the reference electrode from Ag / AgCl (literature) to SCE (present disclosure). The rationale could also be due to the interaction between the drug carrier (Bulk ZnO) and the drugs (ECOSPRIN (with ECOSPRIN-I) and CITICOLINE in the COMBINATION DRUG PRODUCT). Although in the reverse scan, the reduction peaks of ECOSPRIN (with ECOSPRIN-I) are noticed, it is completely suppressed in the forward scan. The rationale behind the absence of oxidation peak of any component of ECOSPRIN (with ECOSPRIN-I) in the forward scan could be attributed to the higher concentration of CITICOLINE in the ZnO tagged composition. Diffusion coefficient of the drug in physiological conditions employing electrochemical studies and Randle – Sevcik equation as given below. ip=2.69*105D1 / 2v1 / 2Cn3 / 2, where, C = 0.5M for CITICOLINE, and C = 0.075M for ECOSPRIN (with ECOSPRIN- I); n=1; v=1 to 200 mV / s; ip is the peak current from cyclic voltametric studies in mA. This resulted in the D values of 5.69*10-12cm2 / s for ZnO tagged ECOSPRIN (with ECOSPRIN-I), 4.06*10-13cm2 / s for ZnO tagged CITICOLINE, and 3.69*10-13cm2 / s for the ZnO tagged COMBINATION DRUG PRODUCT. Thus, DCombined < DCiticholine < DEcospirin. The trend in diffusion coefficient of the drugs indicate the fact that in the case of the ZnO tagged COMBINATION DRUG PRODUCT formulation, the drug diffuses into the system more effectively due to the protonation of the heteroatoms on the cytidine and choline moiety and acidity increase in the system by formation of salicylic acid and acetic acid by hydrolysis of aspirin in ZnO tagged ECOSPRIN. This pushes the pH of the system towards the physiological pH of 5.5, hence facilitating easy oxidation, hydrolysis of the drug leading to facile adsorption of neurotransmitters such as choline by the system and assist in the treatment of patients with stroke possibilities, avoidance of recurrence of stroke, in autistic patients (patients with special needs and abilities), the ZnO tagged COMBINATION DRUG PRODUCT will assist in not only as neurotransmitter after hydrolysis, the drug carrier ZnO acts as the Zn supplement for the system to enhance the absorption of the choline (neurotransmitter) formed during the breakdown of the drug in the body at pH=5.5 in comparison with the individually prescribed and orally administered pharmaceutical formulations of ZnO tagged ECOSPRIN and ZnO tagged CITICOLINE. In summary, The ZnO tagged pharmaceuticals exhibit good coordination with the Pt electrode surface, breaking down of the drug within the potential window of aqueous medium (-1.2 to 1.2V) (the breaking down of the ZnO tagged drug mimics the intended elements required from a drug for a specific biological effect in a human body condition). As discussed in the background of the disclosure, the drugs produced currently by pharmaceutical companies, especially when taken orally are protonated by HCl in the stomach. Based on the drug formula, by such protonation, more and more acids are released as the drugs are digested (for example, release of phosphoric acid in case where the drug includes citicoline having Mol. Formula: C14H26N4O11P2 or C14H27N4O11P2+salt), which makes the pH of the physiological medium much more acidic (locally), thus making it difficult to release the desired product for bioavailability, which necessitates intake of higher doses of the drug with the aim of achieving bioavailability of the drug in the desired amount. Therefore, orally administered drugs currently available are always taken in higher doses of mg, and if the amount of drug taken is high, more protons are released, adding to the acidic environment problem as stated above. As a solution, with the teachings of the present disclosure, the ZnO tagged drug, when taken orally, ZnO takes up the released protons by protonating the Oxygen (O2-) in ZnO instead of protonating the drug. This initiates the facile break-down of the drug to the desired products useful to treat the specific disorder in the body. Hence release of any acids e.g., phosphoric acid does not deviate the physiological pH beyond 5.5. Hence, with the ZnO tagged drug systems of the present disclosure, which eliminates the formation of large amounts of acids, and the physiological pH remains maintained in the system without causing undue hindrance for release of the desired products from the drug for bioavailability, which ultimately greatly increase the bioavailability of the drugs, paving the way to intake of substantially lesser amount of ZnO tagged pharmaceuticals to treat a specific disorder. In-vitro analysis of ZnO tagged CITICOLINE on human blood sample Table 9 summarises the parameters indicating the observations from the treatment of the blood samples with the Drug Delivery system (DDS) i.e., the ZnO tagged COMBINATION DRUG PRODUCT at different concentrations. − The blood samples are collected from volunteer donors with their consent. − The blood samples were collected from donor with previous stroke history and under the prescription of blood thinner and cholesterol control medicines along with neurotransmitters to assist motor controls. − The test / criteria exclude samples from donors with health risk or medical condition, such as diabetes, heart risk, cholesterol, genetic disorders, interactive or abusive drugs intake history and blood diseases such as anaemia, leukaemia, etc. − The blood probes followed the norms / policy of the Health Services of India including utility of disposable syringes, incubators to carry the blood samples and also followed the ASTM F1984-99, ASTM F2888-13 procedures. − The time elapsed from the collection of the sample to the conducting of invitro analysis is approximately 25 minutes. − The blood samples were incubated with the drugs at different concentrations from 15, 25, 62.5, 125 and 250 µg / ml of the drug in different vials for 24 hrs and the appropriate parameter estimations were performed. Baseline in Table 9 indicates the parameters of the collected blood sample without any treatment with the ZnO tagged pharmaceutical. Control in Table 9 indicates the parameters of the collected blood sample, wherein the collected blood sample is treated with negligible amount (in volume of nanogram or picogram level) of the ZnO tagged pharmaceutical. DDS in Table 9 = Drug Delivery system i.e., ZnO tagged COMBINATION DRUG PRODUCT Table 9 Parameters Base Contr DDS DDS DDS DDS DDS Biological Ref. line ol 250 125 62.5 31.25 15.16 interval µg / ml µg / ml µg / ml µg / ml µg / ml Complete blood count RBC count (millions / cmm) 5.75 5.3 5.27 5.06 4.69 5.37 5.52 4.5-6.5 hemoglobin (g / dl) 13.7 13.1 12.6 11.9 10.5 12.2 12.5 13.5-18 pcv(Haematocrit) (%) 47.8 46.2 37.2 35.5 36.7 38.5 39.9 40-54 mean corpuscular volume (fL) 83.3 87.7 70.2 70.2 78.2 71.7 71.1 76-96 mean corpuscular Hemoglobin 23.8 22.9 23.9 23.5 22.4 22.7 22.6 27-32 (pg) mean corpuscular Hb 28.6 28.4 27.3 28.5 28.7 29.7 29.6 30-35 concentration (g / dl) Leucocytes total leucocyte count 11,28 8500 2230 3000 6010 7130 7500 4000-11000 (cells / cmm) 0 Differential count Neutrophils (%) 66.6 55.6 25.1 39.6 59.8 60.5 54.5 40-75 Lymphocytes (%) 22.8 29.5 58.7 43.5 25.6 28.5 32.6 20-45 Monocytes (%) 5.2 9.1 4.6 8.1 9 5.6 6.5 2.0-10.0 Eosinophils (%) 5.4 5.1 11.6 8.1 4.6 4.6 5.2 1.0-6.0 Basophils (%) 0.1 0.7 0 0.7 1 0.8 1.2 0-1.0 Platelets platelet count (cells / cmm) 2,88,0 2,83,0 1,40,0 1,73,0 2,70,0 3,18,0 2,82,0 150000-400000 00 00 00 00 00 00 00 mean platelet volume(MPV) 10 9 10.9 10.9 9 10.7 11 7.2-11.7 (fL) blood group & Rh type B +ve NA NA NA NA NA NA - prothrombin time prothrombin time (sec) 14.1 11.7 12.2 12.9 11.8 13.3 12.1 9.3-14.0 sec PT(INR) value 1.19 0.99 1.03 1.09 1 1.13 1.03 0.8-1.2 with oral anticoagulant t / t: 2.0-3.0 with mechanical prosthetic vale:2.5-3.5 activated partial 31.9 25.9 27.9 27 25.8 28.1 27.2 25.0-43.0 thromboplastin time (sec) Viscosity (mPaS or cPa) 5.12 4.56 3.85 4.08 4.08 4.12 4.63 3.85 – 5.3 Table 9 shows that substantially lesser amount of ZnO tagged pharmaceutical provides the desired efficacy and bioavailability. The amount of drug required is of the order of 1000 times lesser by the ZnO tagged pharmaceutical in comparison to the untagged form. While the recommended / prescribed drugs for a person suffering from neurological disorder e.g., a stroke are Ecospirin 75 mg + Citicoline 500 mg, the treatment of the same disorder with the ZnO tagged pharmaceuticals of the present disclosure is achievable with only a few µg of the ZnO tagged pharmaceuticals per ml of blood (15.16 µg / ml to 250 µg / ml as shown in Table 9). While the present inventors have chosen ZnO as the preferred tagging metal oxide for tagging the pharmaceuticals, other metal oxides that would provide similar efficacy and bioavailability may also be used by a person skilled in the art. COMPLETE BLOOD COUNT: − The RBC count of baseline, control and ZnO tagged COMBINATION DRUG PRODUCT treated blood cells is greater than 5, which is well within the biological reference level of 4.5-6.5. − Haemoglobin decreases on treatment with ZnO tagged COMBINATION DRUG PRODUCT from 13.7 baseline value to around 12 upon treatment with ZnO tagged COMBINATION DRUG PRODUCT. This may be due to interaction of drug carrier with the Fe2+of Haemoglobin, which can be improved upon proper iron intake. − The Haematocrit test indicating the Packed Cell Volume (PCV) is around 47 for baseline and control whereas reduces to 35-40 in case of treatment with ZnO tagged COMBINATION DRUG PRODUCT. This is consistent with Haemoglobin reduction on treatment with ZnO tagged COMBINATION DRUG PRODUCT. Although the PCV has reduced after treatment with ZnO tagged COMBINATION DRUG PRODUCT, it is still close to the lower limit of the biological reference interval of 40 – 54. So proper iron intake along with ZnO tagged COMBINATION DRUG PRODUCT ZnO tagged COMBINATION DRUG PRODUCT would mitigate the induced Haematocrit by ZnO tagged COMBINATION DRUG PRODUCT alone. − Mean Corpuscular Volume (MCV) is greater than 80 indicating good volume of RBC and non-anaemic condition. Upon treatment with ZnO tagged COMBINATION DRUG PRODUCT the MCV reduces to 71 then increases to 78 and again falls to 70, thereby making the average value to be ~ 72.22 this is on the lower limit of the biological reference interval of 76-96. Indicating the fact that the carrier or the drug itself is affecting the MCV. This may not be a huge immediate concern but in long run may affect the RBC in the subject. − Mean Corpuscular Haemoglobin (MCH) is identified to be on the lower side for baseline, control as well as on treatment with ZnO tagged COMBINATION DRUG PRODUCT. ZnO tagged COMBINATION DRUG PRODUCT seems to have no great effect on MCH, indicating that the oxygen carrying ability of the individual under consideration is already on the lower side and might cause mild headache. − Mean Corpuscular Haemoglobin Concentration (MCHC) is identified to be on the lower side for baseline, control as well as on treatment with ZnO tagged COMBINATION DRUG PRODUCT. ZnO tagged COMBINATION DRUG PRODUCT seems to have no great effect on MCHC, indicating that the oxygen carrying ability of the individual under consideration is already on the lower side. As ZnO tagged COMBINATION DRUG PRODUCT has no great influence on MCHC, it is evident that the drugs administered has the effect of reduction in MCHC. LEUCOCYTES: The baseline value is higher than the biological reference range of 4000 – 11000 but reduces on treatment with ZnO tagged COMBINATION DRUG PRODUCT. Although the reduction in leucocytes count is evident, only at higher concentration of ZnO tagged COMBINATION DRUG PRODUCT that the range falls to below lower limit. The rationale behind this observation might be attributed to the interaction of Drug carrier on the leucocytes of the subject. In addition, the monocytes and lymphocytes seem to increase at higher concentration of ZnO tagged COMBINATION DRUG PRODUCT demonstrating the fact that the T and B cells are produced more by the subject when it encounters the ZnO tagged COMBINATION DRUG PRODUCT. This increases the possibility of increased immune response, but at the same time the risk of overproduction of immune cells in the subject. The higher percentage of eosinophils at higher dosage of ZnO tagged COMBINATION DRUG PRODUCT demonstrates the response by the subject towards the drug carrier as an antigen or foreign substance analogous to parasites or bacteria. The drug carrier seems to increase the immune response towards parasitic infections (anti-bacterial functionality). PLATELETS: The platelet count of the subject is absolutely the average between the lower and upper limit of the biological reference value of 1,50,000 to 4,00,000. The platelet decreases with increase in the dosage of ZnO tagged COMBINATION DRUG PRODUCT. At very high dose of 250 µg / l of ZnO tagged COMBINATION DRUG PRODUCT, the platelet count falls below the lower limit to 1,40,000. Except for very high concentration of ZnO tagged COMBINATION DRUG PRODUCT, the platelet count is within the biological reference value for other lower concentrations of ZnO tagged COMBINATION DRUG PRODUCT. PROTHROMBIN TIME: The prothrombin time which indicates the clotting time of the blood is perfectly within the biological reference value in all units. This concludes that the subject’s blood does not clot fast and hence the risk of blood clot in the artery or veins, stroke or heart attack due to blood clot is meagre. INFERENCES: From the above tests, results and discussion, it is clear that ZnO tagged pharmaceuticals can act as efficient drug delivery systems without cytotoxicity, good cell viability, good immune response, together with Zn supplement for the subject. Advantages: The ZnO tagged pharmaceuticals and the method of ZnO tagging of the present disclosure has the following non-limiting advantages. − ZnO tagged pharmaceuticals exhibit improved drug delivery. − Physical ZnO tagging of pharmaceuticals are less expensive. − Absence of chemical tagging drastically lessens the burden on the environment. − ZnO tagged pharmaceuticals provide Zn supplement to the body. − ZnO tagged pharmaceuticals suppress formation of large amounts of acid in the stomach that would otherwise adversely affect the release of the desired products from the drug for bioavailability. − Substantially lesser amount of ZnO tagged pharmaceutical provides the desired efficacy and bioavailability. The amount of ZnO tagged pharmaceutical required is of the order of 1000 times lesser in comparison to the untagged form. Applications: The ZnO tagged pharmaceuticals and the method of ZnO tagging of the present disclosure has the following non-limiting industrial applications. − Effective and efficient drug delivery. Although the present disclosure is described in terms of certain preferred embodiments, it is to be understood that they have been presented by way of example, and not limitation. Thus, the present disclosure should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.

Claims

CLAIMS 1. A therapeutic composition to be administered to an animal with a specific disorder comprising: a Zinc Oxide (ZnO) nanoparticles tagged pharmaceutical.

2. The therapeutic composition to be administered to an animal with a specific disorder as claimed in claim 1 is administered orally.

3. The therapeutic composition to be administered to an animal with a specific disorder as claimed in claim 1 is in the form of a tablet, or a capsule, or a syrup.

4. The therapeutic composition to be administered to an animal with a specific disorder as claimed in claim 1, wherein the amount of ZnO nanoparticles tagged pharmaceutical required to treat the specific disorder is of the order of 1000 times lesser in comparison to the same drug in its untagged form.

5. A method of forming a Zinc Oxide (ZnO) nanoparticles tagged pharmaceutical comprising the steps of: − obtaining a pharmaceutical powder; − adding Zinc Oxide (ZnO) powder to the pharmaceutical powder; and − grinding together the pharmaceutical powder and the ZnO powder in the presence of acetone or isopropanol as solvent, and leaving for a few minutes at room temperature to form a fine powder mixture of ZnO tagged pharmaceutical.

6. The method as claimed in claim 5, wherein the fine powder mixture is of particle size of 500 nm to 700 nm.

7. The method as claimed in claim 5, wherein, when the pharmaceutical before ZnO tagging is in the form of a tablet, the pharmaceutical powder is obtained by grinding the tablet.

8. The method as claimed in claim 5, wherein, when the desired pharmaceutical before ZnO tagging includes two or more tablets of different functionalities to be administered together for a specific disorder, the pharmaceutical powder is obtained by grinding the tablets of different functionalities, and mixing them together in the presence of acetone or isopropanol solvent.

9. The method as claimed in claim 5, wherein the pharmaceutical before ZnO tagging is a pharmaceutical or a combination of pharmaceuticals available in the market under prescription by a physician.

10. The method as claimed in claim 5, wherein the pharmaceutical before ZnO tagging is an over-the-counter (OTC) medicine, or a combination of different OTC medicines.

Citation Information

Patent Citations

  • Zinc oxide-based nano-drug composition, and preparation method and application thereof

    CN105853373A